Conductive Interstitial Thermal Therapy (CITT) device evaluation in VX2 rabbit model

Gal Shafirstein, Leah Hennings, Yihong Kaufmann, Petr Novak, Eduardo G. Moros, Scott Ferguson, Eric Siegel, Vicki Klimberg, Milton Waner, Paul Spring

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

We have developed a conductive interstitial thermal therapy (CITT) device to precisely and reliably deliver controlled thermal doses to the surgical margins at the cavity site following tumor resection, intraoperatively. The temperature field created by CITT ablation of a perfused tissue was modeled with a finite element package Femlab™. The modeling suggested that a maximum probe temperature of 120°C and an ablation time of 20 minutes were required to ablate highly perfused tissue such as the VX2 carcinoma. Deployable pins enable faster and more reliable thermal ablation. The model predictions were tested by thermal ablation of VX2 carcinoma tumors implanted in adult New Zealand rabbits. The size of the ablated region was confirmed with a viability stain, triphenyltetrazolium chloride (TTC). Histopathological examination revealed 3 regions in the ablated area: a carbonized region (1-3 mm); a region that contained thermally fixed cells; and an area of coagulated necrosis cells. Cells in the thermally fixed region stained for PCNA (proliferating cell nuclear antigen) and were bounded by the carbonized layer at the cavity wall, and by necrotic cells that exhibit nuclear fragmentation and cell dissociation, 5 to 10 mm away from the CITT probe. Adjacent tissue outside the target region was spared with a clear demarcation between ablated and normal viable tissue. It is suggested that the CITT device can be used, clinically, to inhibit local recurrence by creating negative surgical margins following the resection of a primary tumor in non-metastatic early staged tumors.

Original languageEnglish (US)
Pages (from-to)235-245
Number of pages11
JournalTechnology in Cancer Research and Treatment
Volume6
Issue number3
StatePublished - Jun 2007
Externally publishedYes

Fingerprint

Hot Temperature
Rabbits
Equipment and Supplies
Therapeutics
Neoplasms
Carcinoma
Temperature
Proliferating Cell Nuclear Antigen
Cell Wall
Necrosis
Coloring Agents
Recurrence
Margins of Excision

Keywords

  • Conductive interstitial thermal therapy (CITT)
  • Finite element method (FEM)
  • Mathematical modeling
  • PCNA (proliferating cell nuclear antigen
  • Thermal ablation
  • Triphenyltetrazolium chloride (TTC)
  • VX2 carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Shafirstein, G., Hennings, L., Kaufmann, Y., Novak, P., Moros, E. G., Ferguson, S., ... Spring, P. (2007). Conductive Interstitial Thermal Therapy (CITT) device evaluation in VX2 rabbit model. Technology in Cancer Research and Treatment, 6(3), 235-245.

Conductive Interstitial Thermal Therapy (CITT) device evaluation in VX2 rabbit model. / Shafirstein, Gal; Hennings, Leah; Kaufmann, Yihong; Novak, Petr; Moros, Eduardo G.; Ferguson, Scott; Siegel, Eric; Klimberg, Vicki; Waner, Milton; Spring, Paul.

In: Technology in Cancer Research and Treatment, Vol. 6, No. 3, 06.2007, p. 235-245.

Research output: Contribution to journalArticle

Shafirstein, G, Hennings, L, Kaufmann, Y, Novak, P, Moros, EG, Ferguson, S, Siegel, E, Klimberg, V, Waner, M & Spring, P 2007, 'Conductive Interstitial Thermal Therapy (CITT) device evaluation in VX2 rabbit model', Technology in Cancer Research and Treatment, vol. 6, no. 3, pp. 235-245.
Shafirstein G, Hennings L, Kaufmann Y, Novak P, Moros EG, Ferguson S et al. Conductive Interstitial Thermal Therapy (CITT) device evaluation in VX2 rabbit model. Technology in Cancer Research and Treatment. 2007 Jun;6(3):235-245.
Shafirstein, Gal ; Hennings, Leah ; Kaufmann, Yihong ; Novak, Petr ; Moros, Eduardo G. ; Ferguson, Scott ; Siegel, Eric ; Klimberg, Vicki ; Waner, Milton ; Spring, Paul. / Conductive Interstitial Thermal Therapy (CITT) device evaluation in VX2 rabbit model. In: Technology in Cancer Research and Treatment. 2007 ; Vol. 6, No. 3. pp. 235-245.
@article{3729f74234f149a880df561cce64b7a3,
title = "Conductive Interstitial Thermal Therapy (CITT) device evaluation in VX2 rabbit model",
abstract = "We have developed a conductive interstitial thermal therapy (CITT) device to precisely and reliably deliver controlled thermal doses to the surgical margins at the cavity site following tumor resection, intraoperatively. The temperature field created by CITT ablation of a perfused tissue was modeled with a finite element package Femlab™. The modeling suggested that a maximum probe temperature of 120°C and an ablation time of 20 minutes were required to ablate highly perfused tissue such as the VX2 carcinoma. Deployable pins enable faster and more reliable thermal ablation. The model predictions were tested by thermal ablation of VX2 carcinoma tumors implanted in adult New Zealand rabbits. The size of the ablated region was confirmed with a viability stain, triphenyltetrazolium chloride (TTC). Histopathological examination revealed 3 regions in the ablated area: a carbonized region (1-3 mm); a region that contained thermally fixed cells; and an area of coagulated necrosis cells. Cells in the thermally fixed region stained for PCNA (proliferating cell nuclear antigen) and were bounded by the carbonized layer at the cavity wall, and by necrotic cells that exhibit nuclear fragmentation and cell dissociation, 5 to 10 mm away from the CITT probe. Adjacent tissue outside the target region was spared with a clear demarcation between ablated and normal viable tissue. It is suggested that the CITT device can be used, clinically, to inhibit local recurrence by creating negative surgical margins following the resection of a primary tumor in non-metastatic early staged tumors.",
keywords = "Conductive interstitial thermal therapy (CITT), Finite element method (FEM), Mathematical modeling, PCNA (proliferating cell nuclear antigen, Thermal ablation, Triphenyltetrazolium chloride (TTC), VX2 carcinoma",
author = "Gal Shafirstein and Leah Hennings and Yihong Kaufmann and Petr Novak and Moros, {Eduardo G.} and Scott Ferguson and Eric Siegel and Vicki Klimberg and Milton Waner and Paul Spring",
year = "2007",
month = "6",
language = "English (US)",
volume = "6",
pages = "235--245",
journal = "Technology in Cancer Research and Treatment",
issn = "1533-0346",
publisher = "Adenine Press",
number = "3",

}

TY - JOUR

T1 - Conductive Interstitial Thermal Therapy (CITT) device evaluation in VX2 rabbit model

AU - Shafirstein, Gal

AU - Hennings, Leah

AU - Kaufmann, Yihong

AU - Novak, Petr

AU - Moros, Eduardo G.

AU - Ferguson, Scott

AU - Siegel, Eric

AU - Klimberg, Vicki

AU - Waner, Milton

AU - Spring, Paul

PY - 2007/6

Y1 - 2007/6

N2 - We have developed a conductive interstitial thermal therapy (CITT) device to precisely and reliably deliver controlled thermal doses to the surgical margins at the cavity site following tumor resection, intraoperatively. The temperature field created by CITT ablation of a perfused tissue was modeled with a finite element package Femlab™. The modeling suggested that a maximum probe temperature of 120°C and an ablation time of 20 minutes were required to ablate highly perfused tissue such as the VX2 carcinoma. Deployable pins enable faster and more reliable thermal ablation. The model predictions were tested by thermal ablation of VX2 carcinoma tumors implanted in adult New Zealand rabbits. The size of the ablated region was confirmed with a viability stain, triphenyltetrazolium chloride (TTC). Histopathological examination revealed 3 regions in the ablated area: a carbonized region (1-3 mm); a region that contained thermally fixed cells; and an area of coagulated necrosis cells. Cells in the thermally fixed region stained for PCNA (proliferating cell nuclear antigen) and were bounded by the carbonized layer at the cavity wall, and by necrotic cells that exhibit nuclear fragmentation and cell dissociation, 5 to 10 mm away from the CITT probe. Adjacent tissue outside the target region was spared with a clear demarcation between ablated and normal viable tissue. It is suggested that the CITT device can be used, clinically, to inhibit local recurrence by creating negative surgical margins following the resection of a primary tumor in non-metastatic early staged tumors.

AB - We have developed a conductive interstitial thermal therapy (CITT) device to precisely and reliably deliver controlled thermal doses to the surgical margins at the cavity site following tumor resection, intraoperatively. The temperature field created by CITT ablation of a perfused tissue was modeled with a finite element package Femlab™. The modeling suggested that a maximum probe temperature of 120°C and an ablation time of 20 minutes were required to ablate highly perfused tissue such as the VX2 carcinoma. Deployable pins enable faster and more reliable thermal ablation. The model predictions were tested by thermal ablation of VX2 carcinoma tumors implanted in adult New Zealand rabbits. The size of the ablated region was confirmed with a viability stain, triphenyltetrazolium chloride (TTC). Histopathological examination revealed 3 regions in the ablated area: a carbonized region (1-3 mm); a region that contained thermally fixed cells; and an area of coagulated necrosis cells. Cells in the thermally fixed region stained for PCNA (proliferating cell nuclear antigen) and were bounded by the carbonized layer at the cavity wall, and by necrotic cells that exhibit nuclear fragmentation and cell dissociation, 5 to 10 mm away from the CITT probe. Adjacent tissue outside the target region was spared with a clear demarcation between ablated and normal viable tissue. It is suggested that the CITT device can be used, clinically, to inhibit local recurrence by creating negative surgical margins following the resection of a primary tumor in non-metastatic early staged tumors.

KW - Conductive interstitial thermal therapy (CITT)

KW - Finite element method (FEM)

KW - Mathematical modeling

KW - PCNA (proliferating cell nuclear antigen

KW - Thermal ablation

KW - Triphenyltetrazolium chloride (TTC)

KW - VX2 carcinoma

UR - http://www.scopus.com/inward/record.url?scp=34347397812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347397812&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 235

EP - 245

JO - Technology in Cancer Research and Treatment

JF - Technology in Cancer Research and Treatment

SN - 1533-0346

IS - 3

ER -